Hematologic Malignancies: Translating Discoveries to Novel Therapies

May 6-9, 2017
Westin Boston Waterfront
Boston, Massachusetts

Saturday, May 6

Plenary Session 1: Initiating and Stem Cells in Hematologic Malignancies
4:15 p.m.-5:30 p.m.

Mechanisms of formation and progression of pre-leukemic stem cells
Ulrich G. Steidl, Albert Einstein College of Medicine, Bronx, NY

Hijacking of emergency myelopoiesis pathways in myeloid leukemia
Emmanuelle Passegué, Columbia University Medical Center, New York, New York

1 short talk from proffered abstracts

Break
5:30 p.m.-5:45 p.m.

Welcome Remarks / Opening Keynote Lecture
5:45 p.m.-7:00 p.m.

Engineered T cells: Opportunities and challenges
Carl H. June, University of Pennsylvania, Philadelphia, Pennsylvania

Opening Reception
7:00 p.m.-9:00 p.m.

Sunday, May 7

Continental Breakfast / Networking Roundtables
7:00 a.m.-8:00 a.m.

Plenary Session 2: The Cellular and Molecular Basis of Drug Resistance and Response to Therapy
8:00 a.m.-10:00 a.m.

Genetics and mechanisms of chemotherapy resistance in relapse acute lymphoblastic leukemia
Adolfo Ferrando, Columbia University, New York, New York

Tumor heterogeneity and clonal evolution in CLL in relationship to therapy
Catherine J. Wu, Dana-Farber Cancer Institute, Boston, Massachusetts

Intratumor heterogeneity and its role in therapeutic escape in multiple myeloma
Rodger E. Tiedemann, Princess Margaret Cancer Centre, Toronto, Ontario, Canada
2 short talks from proffered abstracts

**Break**
10:00 a.m.-10:30 a.m.

**Plenary Session 3: Chemical Biology**
10:30 a.m.-1:00 p.m.

Title to be announced
Nathanael S. Gray, Dana-Farber Cancer Institute, Boston, Massachusetts

**Therapeutic targeting of epigenetic regulators in acute leukemia**
Jolanta E. Grembecka, University of Michigan, Ann Arbor, Michigan

**Targeting the CRL4<sub>CRBN</sub> E3 ligases for treatment of hematological cancers**
Rajesh Chopra, The Institute for Cancer Research, London, United Kingdom

**Targeted therapies as molecular probes for comprehensive pre-clinical evaluation**
Mark Dawson, Peter MacCallum Cancer Center, Melbourne, Victoria, Australia

2 short talks from proffered abstracts

**Poster Session / Lunch**
1:00 p.m.-3:00 p.m.

**Plenary Session 4: Aberrant RNA Metabolism**
3:00 p.m.-5:00 p.m.

**Spliceosome gene mutations in MDS: Biology and potential therapeutic strategies**
Matthew J. Walter, Washington University School of Medicine, St. Louis, Missouri

**The role of malignant RNA editing in leukemia stem cell generation**
Catriona H. M. Jamieson, UCSD Moores Cancer Center, La Jolla, California

**RNA regulators and the control of self-renewal**
Michael G. Kharas, Memorial Sloan Kettering Cancer Center, New York, New York

2 short talks from proffered abstracts

**Plenary Session 5: Initiating and Stem Cells in Hematologic Malignancies II**
5:00 p.m.-6:00 p.m.

Title to be announced
Benjamin L. Ebert, Brigham & Women's Hospital, Boston, MA

2 short talks from proffered abstracts
Monday, May 8

Continental Breakfast / Networking Roundtables
7:00 a.m.-8:00 a.m.

Plenary Session 6: Genomics
8:00 a.m.-10:30 a.m.

Genetic predisposition to hematopoietic malignancies
Lucy A. Godley, University of Chicago, Chicago, Illinois

Title to be announced
Elli Papaemmanuil, Memorial Sloan Kettering Cancer Center, New York, New York

Title to be announced
Charles G. Mullighan, St. Jude Children's Research Hospital, Memphis, Tennessee

CRISPR-Cas9 genetic screens uncover a B cell receptor-MYD88 superpathway in diffuse large B cell lymphoma
Louis M. Staudt, National Cancer Institute, Bethesda, Maryland

2 short talks from proffered abstracts

Break
10:30 a.m.-11:00 a.m.

Plenary Session 7: Cell Death Pathways
11:00 a.m.-1:00 p.m.

Directing blood cancer therapy with mitochondrial BH3 profiling
Anthony G. Letai, Dana-Farber Cancer Institute, Boston, Massachusetts

CDK6: At the interface of Rb and p53
Veronika Sexl, VetmedUni, Institute of Pharmacology and Toxicology, Vienna, Austria

Immunomodulatory therapy of multiple myeloma with IAP antagonists
Marta Chesi, Mayo Clinic Arizona, Scottsdale, Arizona

2 short talks from proffered abstracts

Lunch / Networking Roundtables
1:00 p.m.-3:00 p.m.

Plenary Session 8: Immunotherapy
3:00 p.m.-5:00 p.m.

Targeting CARs to the TRAC locus enhances T cell potency
Michel Sadelain, Memorial Sloan Kettering Cancer Center, New York, New York

Engineering effective and safe T cell therapy
Stanley R. Riddell, Fred Hutchinson Cancer Research Center, Seattle, Washington
Targetable genetic bases of immune evasion in lymphoma
Margaret A. Shipp, Dana-Farber Cancer Institute, Boston, Massachusetts

Epigenetic regulation of cancer immune surveillance processes
Ricky W. Johnstone, Peter MacCallum Cancer Center, Melbourne, Australia

Panel Discussion: Immunotherapy
5:00 p.m.-5:45 p.m.

Tuesday, May 9

Continental Breakfast / Networking Roundtables
7:00 a.m.-8:00 a.m.

Plenary Session 9: Epigenetics
8:00 a.m.-10:00 a.m.

Role of mutations in epigenetic regulators in pathogenesis of myeloid malignancies
Ross L. Levine, Memorial Sloan Kettering Cancer Center, New York, New York

Deregulation and oncogenic functions of the NSD2/MMSET histone methyl transferase in hematological malignancies
Jonathan D. Licht, University of Florida Health Cancer Center, Gainesville, Florida

Epigenetic program in aging and MDS
Maria E. Figueroa, University of Miami, Miami, Florida

2 short talks from proffered abstracts

Break
10:00 a.m.-10:15 a.m.

Plenary Session 10: Tumor Microenvironment and Tumor-Host Interaction
10:15 a.m.-11:45 a.m.

Metabolic vulnerabilities in AML
David T. Scadden, Massachusetts General Hospital, Boston, Massachusetts

Image-based tracking of cancer heterogeneity and therapy resistance
Tannishtha Reya, University of California San Diego, La Jolla, California

Targeting immune receptor mutations in lymphoma
Hans-Guido Wendel, Memorial Sloan Kettering Cancer Center, New York, New York

Departure
12:30 p.m.